Monitor the company's final Q1 2026 earnings release for confirmation of this IPR&D charge and any additional details on the underlying transactions. The charge is non-recurring but could signal new strategic partnerships or acquisitions.
Price Chart
Executive Summary
Regeneron Pharmaceuticals expects a $102 million acquired in-process R&D charge in Q1 2026, which will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81. This is a preliminary estimate ahead of final financial statement closing.
Key Facts
- Regeneron expects a $102 million acquired in-process research and development (IPR&D) charge in Q1 2026
- The charge primarily relates to premiums on equity securities purchased, development milestones, and up-front payments from collaboration and licensing agreements
- The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81
- The company notes that actual results may differ from these preliminary estimates as financial statements are not yet finalized
Financial Impact
Approximately $102 million pre-tax charge, reducing EPS by $0.81
Risk Factors
- Actual results may differ from these preliminary estimates
- The IPR&D charge reflects non-cash expenses that could impact investor perception of profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-040661 |
| Document: 0001104659-26-040661-index-headers.html | 0001104659-26-040661 |
| Document: 0001104659-26-040661-index.html | 0001104659-26-040661 |
| Document: 0001104659-26-040661.txt | 0001104659-26-040661 |
| 8-K Data (Synthetic) | 0001104659-26-040661 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | Insider Cluster | $843.47 $781.49 | ▼ −7.35% | ▼ −6.20% | $735.20 (−12.84%) |
Aug 24, 2026 5w ago | Court Ruling | $828.50 $799.08 | ▼ −3.55% | ▼ −4.02% | $735.20 (−11.26%) |
Aug 20, 2026 6w ago | Press Release | $826.64 $807.71 | ▼ −2.29% | ▼ −3.40% | $735.20 (−11.06%) |
Aug 12, 2026 7w ago | Insider Cluster | $797.99 $840.84 | ▲ +5.37% | ▲ +5.81% | $735.20 (−7.87%) |
Aug 11, 2026 7w ago | Court Ruling | $797.00 $807.57 | ▲ +1.33% | ▲ +1.73% | $735.20 (−7.75%) |
Jul 30, 2026 9w ago | 8-K | $738.34 $772.11 | ▲ +4.57% | ▲ +0.95% | $735.20 (−0.43%) |
Jul 30, 2026 9w ago | Press Release | $738.34 $772.11 | ▲ +4.57% | ▲ +0.95% | $735.20 (−0.43%) |
Jul 27, 2026 9w ago | Press Release | $695.18 $759.24 | ▼ −9.21% | ▼ −6.95% | $735.20 (−5.76%) |
Jul 17, 2026 11w ago | Press Release | $676.69 $651.91 | ▼ −3.66% | ▼ −2.97% | $735.20 (+8.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access